PROGRAM and ABSTRACTS

Fifth International Conference on Malignant Lymphoma

June, 9-12, 1993

Lugano, Switzerland
PROGRAM and ABSTRACTS

Fifth International Conference on Malignant Lymphoma

June, 9-12, 1993

Lugano, Switzerland

Organizing Committee:
F. Cavalli (Bellinzona)
G. Bonadonna (Milan)
A. Hagenbeek (Rotterdam)
T.A. Lister (London)
J.E. Ultmann (Chicago)
R. Zittoun (Paris)

Advisory Board:
C.W. Berard (Memphis)
B. Coiffier (Lyon)
D. Crowther (Manchester)
V. Diehl (Cologne)
S.B. Murphy (Chicago)
H. Rappaport (Duarte)
S.A. Rosenberg (Stanford)
M. Rozencweig (Wallingford)
R. Somers (Amsterdam)
H. Stein (Berlin)
J. Wagstaff (Amsterdam)
R.C. Young (Philadelphia)


Neupogen Brief Prescribing Information Please refer to package insert before prescribing Neupogen. Indications: Reduction in duration of neutropenia and incidence of febrile neutropenia after established cytotoxic chemotherapy for non-myeloid malignancy; reduction in duration of neutropenia and clinical sequelae after myelosuppressive therapy followed by bone marrow transplantation.

Dosage and Administration: Adults. Established cytotoxic chemotherapy 0.5 MU (5 micrograms)/kg/day by subcutaneous injection, or by intravenous infusion over 30 minutes. Continue treatment until after expected nadir and recovery of neutrophil count. Treatment is to be given only in collaboration with an oncology/hematology centre. Myelosuppressive therapy followed by bone marrow transplantation 1.0 MU (10 micrograms)/kg/day given as a 30 minute or 24-hour intravenous infusion or 24-hour subcutaneous infusion. Not to be started within 24 hours of bone marrow infusion. Once the neutrophil nadir has passed and neutrophil count has exceeded 1.0 x 10^9/L for 3 consecutive days, reduce dose to 0.5 MU/kg/day. If count is maintained at >1.0 x 10^9/L for a further 3 days, discontinuance Neupogen, if neutrophil count decreases to <1.0 x 10^9/L during treatment, dose of Neupogen should be re-established as above. Elderly. No specific dose recommendations. Children. Safety and efficacy not yet established. Administration Neupogen is for s.c. or i.v. administration. Neupogen should be diluted in 5% glucose Intravenous Solution BP for i.v. use. Dilute below 0.2 MU (2 micrograms)/ml not recommended. When diluted below 1.5 MU/ml, add human serum albumin to a final concentration of 2 mg/ml. Diluted Neupogen solution should not be prepared more than 24 hours before use. Neupogen and diluted Neupogen solutions should be stored at 2-8°C. Neupogen should not be diluted with saline. Contraindications: Known hypersensitivity to component or constituents. Not to be used for cytotoxic drug escalation beyond established regimen. Pregnancy: Risk to human fetus unknown. Some teratogenic effect in rabbits. Not recommended in nursing women. Precautions: Safety and efficacy not established in myeloblastic, acute or chronic myelogenous leukemia. Neupogen (WBC>1.0 x 10^9/L occurs at doses above 0.3 MU (3 micrograms)/kg/day in less than 5% of patients. Regular haematological monitoring recommended. Bone marrow monitoring advised in osteoplastic patients being treated for longer than 6 months. Use of Neupogen in severe renal or hepatic impairment not recommended. Effect on graft-versus-host disease not yet defined. Neupogen effects may be diminished by impaired pregnanite depletion following extensive chemotherapy. Virotherapy. Drug Interactions: Neupogen treatment not recommended in period 24 hours before to 24 hours after chemotherapy. Side Effects and Adverse Reactions: Musculoskeletal pain, urinary abnormalities (predominantly dysuria, rarely haematuria/proteinuria), reversible dose-dependent elevations of liver enzymes and serum creatinine, acute, transient decrease in blood pressure, occasional reports of vascular disorders after high dose chemotherapy, rarely cutaneous vasculitis in long-term use. Neupogen is a trademark of Amgen Inc.

Full prescribing information is available on request from: PHNeupogen/Genzyme Team. F. Hoffmann-La Roche Ltd., Grenzacherstrasse, Bldg. 4026, Basel, Switzerland.
CONFERENCE SCHEDULE

TUESDAY, JUNE 8, 1993

2:00 p.m. WORKSHOP ON GASTROINTESTINAL LYMPHOMA (Room F) (Attendance by invitation only)

8:00 p.m. FIRST MEETING OF THE EUROPEAN TASK ON MALIGNANT LYMPHOMA (Room C) (Attendance by invitation only)

SATELLITE SYMPOSIA

1:30-5:30 p.m. LONG-TERM RESULTS & CLINICAL PROGRESS IN LYMPHOMA THERAPY (Room A)

4:00-6:15 p.m. IL-3: EFFECTS ON THROMBOPOIESIS, MYELOPOIESIS AND BLOOD PROGENITOR CELL MOBILIZATION (Room B)

6:30-8:30 p.m. LENOGRASTIM: A CONTRIBUTION TO THE OPTIMISATION OF CHEMOTHERAPY TREATMENT IN LYMPHOMA AND SOLID CANCERS (Room A)

WEDNESDAY, JUNE 9, 1993

8:30-9:30 a.m. MEET THE PROFESSOR (Rooms A, B, C, E, F, Villa Ciani)

9:00-10:00 a.m. POSTER SET UP (Villa Ciani)

10:00-10:15 a.m. OPENING OF THE CONFERENCE (Room A)

10:15-11:45 a.m. SESSION 1 - VIROLOGY (Room A)

1:00 p.m. AWARD OF THE SAN SALVATORE FOUNDATION (Room A)

1:15 p.m. HENRY KAPLAN MEMORIAL LECTURE (Room A) MODERN TREATMENT OF MALIGNANT LYMPHOMAS: A MULTIDISCIPLINARY APPROACH?

2:00-3:30 p.m. POSTER VIEWING (Villa Ciani)

3:30-4:15 p.m. POSTERS DISCUSSION WITH DISCUSSION LEADERS (Rooms A, B, C, E, F, Villa Ciani)

4:30-5:30 p.m. CRITICAL REVIEW I (Room A) IS ANAPLASTIC LARGE CELL LYMPHOMA AN ENTITY?

5:30-6:30 p.m. MEET THE PROFESSOR (repetition of the morning)
THURSDAY, JUNE 10, 1993

8:00-9:35 a.m. SESSION 2 - BIOLOGICAL RELEVANCE OF BCL2 PROTEIN (Room A)
10:00-11:50 a.m. SESSION 3 - BIOLOGY OF LYMPHOMAS I (Room A)
1:00-1:40 p.m. KEY NOTE LECTURE I - MOLECULAR EVENTS IN T-CELL DEVELOPMENT (Room A)
1:50-3:50 p.m. SESSION 4 - REVIEW LECTURES ON CLINICAL RESULTS IN HD AND NHLs (Room A)
4:15-5:25 p.m. CRITICAL REVIEW II (Room A)
WHAT DO GROWTH FACTORS CONTRIBUTE TO DOSE INTENSITY AND OUTCOME IN THE TREATMENT OF NHL’S

5:30-6:30 p.m. CRITICAL REVIEW III (Room A)
EARLY ABMT IN THE TREATMENT OF HD

6:30-8:15 p.m. SATELLITE SYMPOSIUM
INTERFERON - ALFA UND G-CSF IN DER HÄMATOLOGIE
(language: german)

FRIDAY, JUNE 11, 1993

8:00-9:45 a.m. SESSION 5 - ABMT IN THE TREATMENT OF NHL (Room A)
8:00-9:30 a.m. SESSION 6 - MOLECULAR BIOLOGY (Room B)
10:00-11:55 a.m. SESSION 7 - BIOLOGY OF LYMPHOMAS II (Room A)
1:00-1:40 p.m. KEY NOTE LECTURE II - MOLECULAR PATHOGENESIS OF NHL (Room A)
1:45-3:45 p.m. SESSION 8 - CLINICAL RESULTS IN THE TREATMENT OF HD (Room A)
4:00-6:15 p.m. SESSION 9 - CLINICAL RESULTS IN THE TREATMENT OF NHL (Room A)
4:00-6:15 p.m. SESSION 10 - CLINICAL-PATHOLOGICAL CORRELATION (Room B)
4:15-6:15 p.m. SESSION 11 - PEDIATRIC LYMPHOMAS (Room C)
6:15 p.m. BUFFET DINNER (Hall Palazzo dei Congressi)
9:00 p.m. BALLET PERFORMANCE (Room A)

SATURDAY, JUNE 12, 1993

8:00-11:30 a.m. SESSION 12 - FUTURE DEVELOPMENTS (Room A)
11:30 a.m. CLOSE
CONFERENCE SCHEDULE

WEDNESDAY, JUNE 9, 1993
8.30 - 11:45 a.m.

8:30-9:30 a.m.  MEET THE PROFESSOR (repeated at 5.30 p.m.)

AIDS-RELATED MALIGNANCIES (Room C)
A.M. Levine, Los Angeles, USA

CUTANEOUS T-CELL LYMPHOMA (Villa Ciani)
R.T. Hoppe, Stanford, USA

MYELOMA (Room F)
B.G.M. Durie, Los Angeles, USA

BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF
LYMPHOMA (Room B)
J.O. Armitage, Omaha, USA

MANTLE CELL LYMPHOMA: CLINICAL FEATURES, TREATMENT, AND
RELATION WITH THE OTHER DIFFUSE SMALL CELL LYMPHOMAS
(Room E)
B. Coiffier, Lyon, France

THE CONTRIBUTION OF HAEMATOLOGICAL GROWTH FACTORS TO
DOSE INTENSIFICATION AND OUTCOME IN THE TREATMENT OF NHL
(Room A)
D. Crowther, Manchester, United Kingdom

9:00-10:00 a.m.  POSTER SET UP (Villa Ciani)

10:00 a.m.  OPENING OF THE CONFERENCE (Room A)
WELCOME AND INTRODUCTORY REMARKS
F. Cavalli, Bellinzona, Switzerland
## SESSION 1 - VIROLOGY (Room A)
Chairman: V. Diehl

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title, Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 a.m.</td>
<td>1 PATHOGENESIS OF EBV IN LYMPHOPROLIFERATIVE DISORDERS IN IMMUNOCOMPROMISED HOST.</td>
<td>E.D. Kieff, Boston, USA</td>
</tr>
<tr>
<td>10:35</td>
<td>2 ROLE OF VIRUSES IN THE ETHIOLOGY OF LYMPHOMAS.</td>
<td>L.M. Weiss, Duarte, USA</td>
</tr>
<tr>
<td>10:55</td>
<td>3 EPSTEIN-BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIONS.</td>
<td>H. Stein, Berlin, Germany</td>
</tr>
<tr>
<td>11:30</td>
<td>5 HODGKIN’S DISEASE AND NASOPHARYNGEAL CARCINOMA SHARE IDENTICAL AND SIMILAR DELETIONS WITHIN THE LATENT MEMBRANE PROTEIN ONCOGENE.</td>
<td>H. Knecht, et al, Lausanne, Switzerland</td>
</tr>
<tr>
<td>11:45</td>
<td></td>
<td>INTERMISSION</td>
</tr>
<tr>
<td>12:00-1:00 p.m.</td>
<td>LUNCH (Room B)</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td></td>
<td>AWARD OF THE SAN SALVATORE FOUNDATION (Room A)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairman: F. Cavalli</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Presentation of the award: P. Alberto, Geneva; G. Bianchi, Lugano</td>
</tr>
<tr>
<td>1:15 p.m.</td>
<td>6 HENRY KAPLAN MEMORIAL LECTURE (Room A)</td>
<td>MODERN TREATMENT OF MALIGNANT LYMPHOMAS: A MULTIDISCIPLINARY APPROACH?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>G. Bonadonna, Milan, Italy</td>
</tr>
<tr>
<td>2:00-3:30 p.m.</td>
<td>POSTER VIEWING (Villa Ciani)</td>
<td></td>
</tr>
<tr>
<td>3:30-4:15 p.m.</td>
<td>POSTERS DISCUSSION WITH DISCUSSION LEADERS</td>
<td>SESSION 1 - CLINICAL-PATHOLOGICAL RESULTS (Room F)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion leader: A. Polliack, Jerusalem, Israel</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Posters N. 17, 19, 21, 22, 23</td>
</tr>
</tbody>
</table>
SESSION 2 - RESIDUAL MASSES (Room E)
Discussion leader: J. Schwarzmeier, Vienna, Austria
Posters N. 26, 27, 28, 29, 30

SESSION 3 - MOLECULAR BIOLOGY (Villa Ciani)
Discussion leader: B.D. Young, London, United Kingdom
Posters N. 39, 40, 41, 42, 43, 44, 45, 46

SESSION 4 - HODGKIN’S DISEASE (Room A)
Discussion leader: J.E. Ulmann, Chicago, USA
Posters N. 64, 65, 67, 71, 78, 80, 82, 85, 86, 87

SESSION 5 - LOW-GRADE LYMPHOMAS (Room B)
Discussion leader: S.J. Horning, Stanford, USA
Posters N. 98, 99, 101, 102, 103, 104, 107

SESSION 6 - HIGH-GRADE LYMPHOMAS (Room C)
Discussion leader: B. Coiffier, Lyon, France
Posters N. 111, 112, 113, 114, 115, 118, 121, 122

CRITICAL REVIEW I
IS ANAPLASTIC LARGE CELL LYMPHOMA AN ENTITY? (Room A)
Chairman: F. Cabanillas

4:30-5:30 p.m.

Introduction:
7 CD30 LIGAND: MOLECULAR CLONING AND PATHOBIOLOGICAL ROLE IN CD30-POSITIVE MALIGNANT LYMPHOMAS.  
H.J. Gruss, et al, Seattle, USA

Discussants:
8 PRIMARY CD30 + ANAPLASTIC LARGE CELL LYMPHOMA  
- A DISTINCT CLINICOPATHOLOGIC ENTITY -  
M.E. Kadin, Boston, USA

9 ANAPLASTIC LARGE CELL LYMPHOMA: MORPHOLOGY AND CLINICOPATHOLOGIC CORRELATIONS.  
T. Radaszkiewicz, Vienna, Austria

Concluding remarks:
10 KI-1 POSITIVE LARGE CELL LYMPHOMA: IS IT A CLINICAL ENTITY?  
F. Cabanillas, Houston, USA

5:30-6:30 p.m.  
MEET THE PROFESSOR (repetition of the morning)
THURSDAY, JUNE 10, 1993
8:00-9:35 a.m.

SESSION 2 - BIOLOGICAL RELEVANCE OF BCL2 PROTEIN (Room A)
Chairlady: A.M. Levine

8:00 a.m.  11 BCL2 ANTISENSE OLIGONUCLEOTIDES SUPPRESS T(14;18) B-CELL LYMPHOMA GROWTH IN A SCID-HU MOUSE MODEL.
F.E. Cotter, et al, London, United Kingdom

8:15  12 INTERLEUKIN-4 AND INTERFERON - α INHIBIT APOPTOTIC CELL DEATH AND PREVENT THE LOSS OF THE BCL-2 PROTEIN IN B-CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS IN VITRO.
P. Panayiotidis, et al, London, United Kingdom

8:30  13 PERSISTENCE OF T(14;18) BEARING CELLS IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER MYELOABLATIVE THERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION.
P.W.M. Johnson, et al, London, United Kingdom

8:45  14 POLYMERASE CHAIN REACTION: A REFINED TOOL FOR ASSESSING RESPONSE IN FOLLICULAR LYMPHOMAS.
F. Cabanillas, et al, Houston, USA

9:00  15 REGULATION OF CHEMORESISTANCE BY BCL-2.
J.C. Reed, La Jolla, USA

9:20  16 BCL-2 PROTEIN EXPRESSION IN AGGRESSIVE NON-HODGKIN’S LYMPHOMA.
A NEW ADVERSE PROGNOSTIC FACTOR? A GELA STUDY.
P. Gaulard, et al, Creteil, France

9:35
INTERMISSION

SESSION 3 - BIOLOGY OF LYMPHOMAS I (Room A)
Chairman: R.F. Dorfmann

10:00-11:50 a.m.

10:00 a.m.  17 WHY ARE B-CELL LYMPHOMAS RARE IN ASIA? A PERSONAL VIEW.
K. Nanba, Hiroshima, Japan

10:20  18 EPIDEMIOLOGY OF NON-HODGIN’S LYMPHOMA.
D.D. Weisenburger, Omaha, USA

10:45  19 THE INTERRELATIONSHIP BETWEEN HODGKIN’S DISEASE AND NON-HODGKIN’S LYMPHOMAS.
F.S. Jaffe, Bethesda, USA
THURSDAY, JUNE 10, 1993
10:00-11:50 a.m. (continued)

11:10  20  IS HODGKIN’S DISEASE AN INFECTIOUS DISEASE?
       V. Diehl, Cologne, Germany

11:35  21  HIGH PLASMA LEVELS OF TUMOR NECROSIS FACTOR ALPHA ARE
       CORRELATED WITH ADVERSE PROGNOSTIC FACTORS AND
       ASSOCIATED WITH A POOR OUTCOME IN LYMPHOMA PATIENTS.
       G. Salles, et al, Pierre-Benite, France

11:50
       INTERMISSION

12:00-1:00 p.m.
       LUNCH (Room B)

1:00 p.m.  22  KEY NOTE LECTURE I (Room A)
       T-LYMPHOCYTE FUNCTION AND ONTOGENY IN GENE-TARGETTED
       MUTANT MICE.
       T.W. Mak, Toronto, Canada

SESSION 4 - REVIEW LECTURES ON CLINICAL
RESULTS IN HD AND NHLs (Room A)
Chairmen: G. Bonadonna and R.T. Hoppe

1:50-3:50 p.m.

1:50 p.m.  23  THE TREATMENT OF HODGKIN’S DISEASE.
       S.A. Rosenberg, Stanford, USA

2:20  24  LOW GRADE LYMPHOMA 1993 - STATE OF THE ART.
       S.J. Horning, Stanford, USA

2:40  25  TREATMENT OF AGGRESSIVE NON HODGKIN’S LYMPHOMAS.
       R.J. Fisher, Maywood, USA

3:00  26  RECENT ADVANCES IN MANAGEMENT OF PEDIATRIC LYMPHOMAS.
       S.B. Murphy, Chicago, USA

3:15  27  LATE NON-MALIGNANT COMPLICATIONS OF THE TREATMENT OF
       LYMPHOMAS; EMPHASIS ON LONG-TERM CARDIAC TOXICITY.
       J.M. Cosset, Villejuif, France

3:35  28  CURRENT TREATMENT FOR MULTIPLE MYELOMA.
       B.G.M. Durie, Los Angeles, USA

3:50
       INTERMISSION
THURSDAY, JUNE 10, 1993
4:15-5:25 p.m.

CRITICAL REVIEW II - WHAT DO GROWTH FACTORS CONTRIBUTE TO DOSE INTENSITY AND OUTCOME IN THE TREATMENT OF NHL’S (Room A)
Chairman: G.P. Canellos

Introduction:
29 CYTOKINE EFFICIENCY IN THE TREATMENT OF HIGH-GRADE MALIGNANT NON-HODGKIN LYMPHOMAS: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY WITH INTENSIFIED COP-BLAM ± rhGM-CSF.
M. Engelhard, et al, Essen, Germany

30 COST/BENEFIT OF G-CSF ADMINISTRATION IN OLDER PATIENTS (60-70 YEARS) WITH NON-HODGKIN’S LYMPHOMAS AFTER COMBINATION CHEMOTHERAPY.
S. Monfardini, et al, Aviano, Italy

Discussants:
31 D. Crowther, Manchester, United Kingdom

32 WHAT DO GROWTH FACTORS CONTRIBUTE TO DOSE INTENSITY AND OUTCOME IN THE TREATMENT OF NHL’S.
Ch. Gisselbrecht, Paris, France

Concluding remarks: G.P. Canellos, Boston, USA

CRITICAL REVIEW III
EARLY ABMT IN THE TREATMENT OF HD (Room A)
Chairman: J.O. Armitage

5:30-6:30 p.m.

Introduction:
33 INTENSIVE THERAPY WITH CYCLOPHOSPHAMIDE, BCNU, ETOPOSIDE ± CIPLATIN AND AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR PATIENTS WITH HODGKIN’S DISEASE IN FIRST RELAPSE.
D.E. Reece, et al, Vancouver, Canada

Discussants:
34 A.M. Gianni, Milan, Italy

35 A.H. Goldstone, London, United Kingdom

Concluding remarks: J.O. Armitage, Omaha, USA
FRIDAY, JUNE 11, 1993
8:00-9:45 a.m.

SESSION 5 - ABMT IN THE TREATMENT OF NON-HODGKIN'S LYMPHOMA (Room A)

8:00 a.m.  36 PERIPHERAL BLOOD PROGENITOR CELL: THE SINGLE APHERESIS TRANSPLANT.
            R. Pettengell, et al, Manchester, United Kingdom

8:15       37 COMPARISON OF PERIPHERAL AND BONE MARROW AUTOLOGOUS TRANSPLANTATION FOR LYMPHOMA PATIENTS: A CASE CONTROLLED ANALYSIS OF THE EBMT REGISTRY DATA.
            G. Liberti, et al, Palermo, Italy

8:30       38 MYELOABLATIVE THERAPY WITH AUTOLOGOUS BONE MARROW TRANSPLANTATION AS CONSOLIDATION THERAPY FOR FOLLICULAR LYMPHOMA.

8:45       39 HIGH DOSE THERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION IN FIRST COMPLETE REMISSION FOR ADULT PATIENTS WITH HIGH GRADE NON-HODGKIN'S LYMPHOMA: THE EBMT EXPERIENCE.
            J.W. Sweetenham, et al, Southampton, United Kingdom

9:00       40 AUTOLOGOUS BONE MARROW TRANSPLANTATION VERSUS SEQUENTIAL CHEMOTHERAPY IN FIRST COMPLETE REMISSION AGGRESSIVE NON-HODGKIN'S LYMPHOMA: A STUDY ON 469 PATIENTS (LNH87 PROTOCOL).
            C. Haïoun, et al, Creteil, France

9:15       41 ABMT VS DHAP IN RESIDUAL DISEASE FOLLOWING THIRD GENERATION REGIMENS FOR AGGRESSIVE NON-HODGKIN'S LYMPHOMAS.
            P.L. Zinzani, et al, Bologna, Italy

9:30       42 MYELODYSPLASTIC SYNDROME/ACUTE MYELOGENOUS LEUKEMIA FOLLOWING HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOID MALIGNANCY: CHARACTERIZATION AND RELATIVE RISK.
            J.M. Vose, et al, Omaha, USA

9:45       INTERMISSION
FRIDAY, JUNE 11, 1993
8:00-9.30 a.m.

SESSION 6 - MOLECULAR BIOLOGY (Room B)
Chairmen: T.W. Mak and R. Dalla-Favera

8:00 a.m.  43 TRISOMY 12 IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA DETECTED BY IN SITU HYBRIDIZATION: CORRELATION WITH ADVANCED STAGE DISEASE AND WITH REFRACTORYNESS TO TREATMENT.
W.U. Knauf, et al, Berlin, Germany

8:15  44 A GENE ENCODING AN HOMOLOGUE OF A DROSOPHILA ZINC FINGER PROTEIN IS DISRUPTED BY THE TRANSLOCATIONS INVOLVING BAND 3Q27 IN NON HODGKIN'S LYMPHOMAS.
C. Bastard, et al, Bois-Guillaume, France

8:30  45 A RELIABLE APPROACH FOR SEQUENCING CLONE-SPECIFIC CDR-III REGIONS IN B LYMPHOMA.
C. Straka, et al, Manchester, United Kingdom

8:45  46 PRAD1/CYCLIN D1 OVEREXPRESSION IN NON-HODGKIN'S LYMPHOMA WITH CHROMOSOME 11 BCL-1 REARRANGEMENT.
M.E. Williams, Charlottesville, USA

9:00  47 INVESTIGATION OF THE ACTIVATION STATE OF THE X-CHROMOSOMES IN NON-HODGKIN'S LYMPHOMAS.
A.J. Grierson, et al, Sheffield, United Kingdom

9:15  48 ALTERED EXPRESSION OF THE RETINOBLASTOMA GENE PRODUCT IN HUMAN HIGH GRADE NON-HODGKIN'S LYMPHOMAS.
R. Weide, et al, Marburg, Germany

9:30  INTERMISSION

SESSION 7 - BIOLOGY IN LYMPHOMAS II (Room A)
Chairmen: J. Wagstaff and A. Polliack

10:00-11.55 a.m.

10:00 a.m.  49 ANTIBODY MEDIATED EFFECTOR MECHANISMS.
H. Waldmann, Cambridge, United Kingdom

10:20  50 LYMPHOKINE RECEPTORS: A TARGET FOR IMMUNOTHERAPY OF LYMPHOMAS.
T. A. Waldmann, Bethesda, USA

10:45  51 LYMPHOMAS ARISING IN STATES OF ABNORMAL IMMUNITY.
A.M. Levine, Los Angeles, USA
FRIDAY, JUNE 11, 1993
10:00-11:55 a.m. (continued)

11:10 52 TRANSFORMATION IN FOLLICULAR LYMPHOMA: FREQUENT P53 AND BCL-2 ONCOProTEIN OVEREXPRESSION, CELL PROLIFERATION AND APOPTOSIS.
W.E. Symmans, et al, Houston, USA

11:25 53 INCIDENCE, PREDICTIVE FACTORS AND PROGNOSIS OF HISTOLOGIC TRANSFORMATION IN FOLLICULAR LYMPHOMA.
Y. Bastion, et al, Pierre Benite, France

11:55 INTERMISSION

12:00-1:00 p.m. LUNCH (Room B)

1:00 p.m. 54 KEY NOTE LECTURE II (Room A)
MOLECULAR PATHOGENESIS OF NON-HODGKIN’S LYMPHOMA.
R. Dalla-Favera, New York, USA

SESSION 8 - CLINICAL RESULTS IN THE TREATMENT OF HODGKIN’S DISEASE (Room A)
Chairmen: V. Diehl and S.A. Rosenberg

1:45-3:45 p.m.

1:45 p.m. 55 HODGKIN’S DISEASE IN CHILDREN: COMBINED MODALITY TREATMENT FOR STAGE I A/B AND IIA. RESULTS IN 356 PATIENTS OF THE GERMAN PEDIATRIC STUDY GROUP.
G. Schellong, et al, Münster, Germany

2:00 56 PRELIMINARY RESULTS OF AN EORTC-GPMC CONTROLLED CLINICAL TRIAL IN EARLY STAGE HODGKIN’S DISEASE.
E.M. Noordijk, et al, Leiden, The Netherlands

2:15 57 EARLY-STAGE HODGKIN’S DISEASE: LONG-TERM RESULTS WITH RADIOTHERAPY ALONE OR COMBINED RADIO-CHEMOTHERAPY.
C. Bernasconi, et al, Pavia, Italy

2:30 58 CHLVPP THERAPY FOR HODGKIN’S DISEASE: EXPERIENCE OF 960 PATIENTS. THE INTERNATIONAL CHLVPP TREATMENT GROUP.
J.R. Anderson, et al, Omaha, USA

2:45 59 A RANDOMIZED PHASE III TRIAL OF MOPP/ABV HYBRID VS. SEQUENTIAL MOPP-ABVD IN ADVANCED HODGKIN’S DISEASE. RESULTS OF THE INTERGROUP TRIAL.
J.H. Glick, et al, Philadelphia, USA

3:00 60 HYBRID LOPP/EVA IS NOT BETTER THAN LOPP ALTERNATING WITH EVAP. A PREMATURELY TERMINATED BRITISH NATIONAL LYMPHOMA INVESTIGATION RANDOMISED TRIAL.
B.W. Hancock, et al, Sheffield, United Kingdom
FRIDAY, JUNE 11, 1993
1:45 - 3:45 p.m. (continued)

3:15  61  MVPP VERSUS A SEVEN DRUG HYBRID REGIMEN IN HODGKIN’S DISEASE: RESULTS OF A RANDOMISED TRIAL.
       J.A. Radford, et al, Manchester, United Kingdom

3:30  62  LEUKEMIA RISK FOLLOWING HODGKIN’S DISEASE: RELATION TO TREATMENT FACTORS AND TREATMENT-RELATED BONE MARROW DAMAGE.
       F.E. Van Leeuwen, et al, Amsterdam, The Netherlands

3:45  INTERMISSION

SESSION 9 - CLINICAL RESULTS IN THE TREATMENT OF NON HODGKIN’S LYMPHOMA (Room A)
         Chairman: B. Coiffier and J.H. Glick

4:00 - 6:15 p.m.

4:00 p.m.  63  HIGH SURVIVAL RATE OF CHILDHOOD B-CELL LYMPHOMA AND LEUKEMIA AS RESULT OF THE LMB 89 PROTOCOL OF THE SFOP.
               C. Patte, et al, Villejuif, France

4:15  64  INVOLVED FIELD RADIOTHERAPY IN CLINICAL STAGE I-II LOW GRADE LYMPHOMA.
       M.K. Gospodarowicz, et al, Toronto, Canada

4:30  65  CHLORAMBUCIL/PREDNISON VERSUS CHOP IN SYMPTOMATIC LOW GRADE LYMPHOMAS.
       E. Kimby, et al, Danderyd, Sweden

4:45  66  ON THE INFLUENCE OF HUMAN RECOMBINANT ALPHA-2 INTERFERON ON REMISSION DURATION IN PATIENTS WITH STAGES III AND IV LOW GRADE MALIGNANT NON-HODGKIN’S LYMPHOMA. RESULTS FROM A PROSPECTIVE, RANDOMISED PHASE III CLINICAL TRIAL IN 346 PATIENTS.
       A. Hagenbeek, et al, Rotterdam, The Netherlands

5:00  67  A CONCOMITANT TREATMENT WITH INTERFERON ALFA AND A DOXORUBICIN-CONTAINING REGIMEN IMPROVES SURVIVAL IN HIGH-TUMOR BURDEN FOLLICULAR NON-HODGKIN’S LYMPHOMAS.
       P. Solal-Celigny, et al, Paris, France

5:15  68  A RANDOMIZED PHASE III TRIAL OF PROMACE-MOPP VS MACOP-B IN AGGRESSIVE NON-HODGKIN’S LYMPHOMAS. AN INTERIM ANALYSIS OF THE NON-HODGKIN’S LYMPHOMA CO-OPERATIVE STUDY GROUP.
       G. Santini, et al, Genoa, Italy
FRIDAY, JUNE 11, 1993
4:00 - 6:15 p.m. (continued)

5:30  69  COMPARISON OF CHOP VS. PACEBOM IN DIFFUSE AND LARGE CELL LYMPHOMAS WITH AN ANALYSIS OF OUTCOME IN POOR PROGNOSIS YOUNGER PATIENTS: A BNLI RANDOMISED TRIAL.
D.C. Linch, et al, London, United Kingdom

5:45  70  CHOP VS M-BACOD FOR ADVANCED DIFFUSE NON-HODGKIN’S LYMPHOMA: ASSOCIATION OF LONG-TERM OUTCOME WITH THE INTERNATIONAL INDEX AND WITH LDH ALONE.
L.J. Gordon, et al, Chicago, USA

6:00  71  STAGE, SERUM LDH, AND PERFORMANCE STATUS PREDICT DISEASE PROGRESSION AND SURVIVAL IN HIV-ASSOCIATED LYMPHOMAS.
E.B. Hagemeister, et al, Houston, USA

SESSION 10 - CLINICAL-PATHOLOGICAL CORRELATION (Room B)
Chairpersons: E.S. Jaffe and H. Stein

4:00 - 6:15 p.m.

4:00 p.m.  72  PRIMARY NASAL T CELL LYMPHOMA.
L.M. Weiss, Duarte, USA

4:25  73  T-CELL RICH B-CELL LYMPHOMA AND THEIR RELATIONSHIP TO HODGKIN’S DISEASE.
G. Delsol, Toulouse, France

4:50  74  MANTLE CELL LYMPHOMAS.
C. De Wolf-Peeters, Leuven, Belgium

5:15  75  CD30/KI-1 POSITIVE LYMPHOPROLIFERATIVE DISORDERS OF THE SKIN. CLINICOPATHOLOGIC CHARACTERIZATION OF 92 CASES.
M. Paulli, et al, Pavia, Italy

5:30  76  CORRELATION OF CYTOGENETIC FINDINGS AND HISTOPATHOLOGICAL DIAGNOSES ACCORDING TO THE UPDATED KIEL CLASSIFICATION IN 104 PERIPHERAL T CELL LYMPHOMAS.
B. Schlegelberger, et al, Kiel, Germany

5:45  77  POST-TRANSPLANT LYMPHOMAS THAT EXPRESS T-CELL MARKERS.
E.K. Waller, et al, Stanford, USA

6:00  78  OCCURENCE OF T(14;18)-POSITIVE, MONOCOLONAL PLASMA CELLS FOLLOWING TREATMENT WITH IL-3, IN A PATIENT WITH FOLLICULAR LYMPHOMA.
M.H.H. Kramer, et al, Leiden, The Netherlands
FRIDAY, JUNE 11, 1993
4:15 - 6:15 p.m.

SESSION 11 - PEDIATRIC LYMPHOMAS (Room C)
Chairlady: S.B. Murphy

H.P. Wagner, et al, Berne, Switzerland

4:30 80 CHILDHOOD NON-HODGKIN’S LYMPHOMA OF THE NON-B-CELL TYPE: TREATMENT RESULTS OF THREE BFM TRIALS.
M. Schrappe, et al, Hannover, Germany

4:45 81 B-CELL NEOPLASIA IN CHILDHOOD: RISK GROUP STRATIFICATION, TREATMENT STRATEGY AND PRELIMINARY RESULTS OF TRIAL NHL-BFM 90.
A. Reiter, et al, Hannover, Germany

MINI-SYMPOSIUM
ANAPLASTIC LARGE CELL LYMPHOMAS OF CHILDHOOD
Co-Chairman: M.E. Kadin

5:00 p.m. 82 LARGE CELL ANAPLASTIC LYMPHOMA IN CHILDREN - OUTCOME USING HIGH GRADE B CELL CHEMOTHERAPY.
C.R. Pinkerton, Sutton, United Kingdom

83 IMMUNOPHENOTYPE INFLUENCES SURVIVAL IN PEDIATRIC LARGE CELL LYMPHOMA. A PEDIATRIC ONCOLOGY GROUP STUDY.
R.E. Hutchison, et al, Syracuse, USA

84 CHARACTERISTICS AND TREATMENT OUTCOME FOR 18 CHILDREN WITH CD30 POSITIVE LARGE CELL NON-HODGKIN LYMPHOMA .
J. Sandlund, et al, Memphis, USA

85 PRIMARY ANAPLASTIC LARGE CELL NON HODGKIN LYMPHOMA IN CHILDREN.
M. Massimino, et al, Milan, Italy

86 LARGE CELL ANAPLASTIC LYMPHOMA IN CHILDREN: THERAPEUTIC RESULTS IN 75 PATIENTS TREATED WITH 3 CONSECUTIVE POLYCHEMOTHERAPY REGIMENS.
L. Brugières, et al, Villejuif, France

87 LARGE CELL ANAPLASTIC LYMPHOMA OF CHILDHOOD: A REPORT OF 45 PATIENTS UNIFORMELY TREATED ACCORDING TO THE BFM B-NHL STRATEGY.
A. Reiter, et al, Hannover, Germany
SESSION 12 - FUTURE DEVELOPMENTS (Room A)
Chairmen: T.A. Lister and J.E. Ultmann

8:00 a.m.  88  IN VITRO DRUG SENSITIVITY TESTING OF TUMOUR CELLS FROM PATIENTS WITH NON-HODGKIN'S LYMPHOMA USING THE FLUOROMETRIC MICROCulture CYTOTOXICITY ASSAY.
            P. Nygren, et al, Uppsala, Sweden

8:15      89  IMMUNOTOXINS: IS THERE A POTENTIAL CLINICAL VALUE?
            A. Engert, Cologne, Germany

8:35      90  THERAPY OF REFRACTORY HODGKIN’S DISEASE WITH ANTI-CD30/SAPORIN IMMUNOTOXIN.
            B. Falini, et al, Perugia, Italy

8:50      91  PROSPECTS FOR ANTI-SENSE THERAPY.
            J.T. Magrath, Bethesda, USA

9:10      92  CONSSENSUS MEETING ON THE ROLE OF ABMT (LYON, JUNE, 1993) INCLUDING PRESENTATION OF PARMA-TRIAL.
            B. Coiffier and T. Philip, Lyon, France

9:40      93  FLUDARABINE IN MALIGNANT LYMPHOMA: PRESENT STATUS AND FUTURE POSSIBILITIES.
            M.J. Keating, Houston, USA

10:15     94  2’CHLORODEOXYADENOSINE ACTIVITY IN THE LYMPHOID MALIGNANCIES.
            L.D. Piro, La Jolla, USA

10:35     REPORT ON WORKSHOP ABOUT GI-LYMPHOMAS (LUGANO, JUNE 8, 1993)
            T.A. Lister, London, United Kingdom

11:00     CLOSING REMARKS
            J.E. Ultmann, Chicago, USA

11:30     CLOSE